Changes in Blood-Brain Transfer Parameters Induced by Hyperosmolar Intracarotid Infusion and by Metastatic Tumor Growth

Blasberg, Ronald G.; Gazendam, J.; Patlak, Clifford S.; Shapiro, Wayne; Fenstermacher, Joseph D.

doi:10.1007/978-1-4684-3752-2_24

Cited by 32 publications

(16 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The transport steps that must be considered in systemic chemotherapy for brain tumors include blood flow through the tumor microvasculature and the flux of drug across tumor capillaries. The delivery of drugs to the tumor will be a function of the exchangeable concentration of drug in the blood, the capillary blood flow, and the permeability-surface area product of tumor capillaries with respect to each drug { S , 6,7,18, 321. Subsequently, distribution volume(s) of the drug at equilibrium and the rate(s) of drug metabolism in the tissue will influence drug concentration within the tumor 132, 341.…”

mentioning

confidence: 99%

Regional blood flow in ethylnitrosourea‐induced brain tumors

Blasberg

Kobayashi

Horowitz

et al. 1983

Annals of Neurology

View full text Add to dashboard Cite

Regional blood flow was measured in experimental brain tumors using iodoantipyrine labeled with carbon 14 and quantitative autoradiography. A total of fifteen oligodendrogliomas, sixteen mixed gliomas, one astrocytoma, one ependymoma, and three malignant schwannomas were studied in 9 rats. The mean tumor blood flows for all glioma classifications were similar, averaging 45 +/- 3 (standard error of the mean) ml . hg-1 . min-1. Flow was fairly uniform within individual oligodendrogliomas and there was no apparent correlation between blood flow and tumor size or location. The mixed gliomas were larger than the oligodendrogliomas and had a wider range of blood flow. Small focal areas of necrosis were observed in 7 mixed gliomas, and low flows were usually measured in these regions; these flows were not always the lowest regional values measured within the mixed gliomas or total group of tumors, however. Small tumor regions with increased vascularity, frequently with endothelial cell proliferation, were observed in oligodendrogliomas and to a greater extent in mixed gliomas; these regions were correlated with small elevations in blood flow (10 to 15 ml . hg-1 . min-1) in comparison with surrounding tumor tissue. Brain adjacent to tumor usually had higher blood flows than that in tumor periphery. Hemispheric differences in blood flow related to the site of primary tumor growth were not observed.

show abstract

mentioning

confidence: 99%

Regional blood flow in ethylnitrosourea‐induced brain tumors

Blasberg

Kobayashi

Horowitz

et al. 1983

Annals of Neurology

View full text Add to dashboard Cite

show abstract

“…In general, an inverse relationship was demonstrated between tumor size and F. These characteristics were typical of the Walker 256 metastatic , 68 Regardless of whether a small tumor ( < l m m diameter) was growing in grey or white matter structures, tumor blood flow was indistinguishable from that of surrounding brain tissue. In larger tumors (2 to 5 mm in diameter), F was reduced and inversely related to tumor size.…”

Section: Blood Flowmentioning

confidence: 92%

Application of Quantitative Autoradiographic Measurements in Experimental Brain Tumor Models

Blasberg¹,

Groothuis²,

Molnár³

1981

Semin Neurol

114

View full text Add to dashboard Cite

“…On the anatomical level, tumors promote the formation of new deformed blood vessels that lack the classic BBB tight junction structure [69]. The new deformed blood vessels have no astrocytic proper contact, with increased vesicular density [70] and fenestrations or pores that allow the free paracellular passage of molecules into the brain [71–75]. On the functional level, the vasculature within a primary brain tumor typically has reduced expression of tight junction proteins such as ZO-1, which acts as scaffolding protein to anchor another tight junction protein, occludin, to the endothelial membrane [9,76], which results in increased vascular permeability [77,78].…”

Section: The Brain–tumor Barrier: the Unpredictable Obstaclementioning

confidence: 99%

Novel Treatment Strategies for Brain Tumors and Metastases

et al. 2014

View full text Add to dashboard Cite

This review summarizes patent applications in the past 5 years for the management of brain tumors and metastases. Most of the recent patents discuss one of the following strategies: the development of new drug entities that specifically target the brain cells, the blood–brain barrier and the tumor cells, tailor-designing a novel carrier system that is able to perform multitasks and multifunction as a drug carrier, targeting vehicle and even as a diagnostic tool, direct conjugation of a US FDA approved drug with a targeting moiety, diagnostic moiety or PK modifying moiety, or the use of innovative nontraditional approaches such as genetic engineering, stem cells and vaccinations. Until now, there has been no optimal strategy to deliver therapeutic agents to the CNS for the treatment of brain tumors and metastases. Intensive research efforts are actively ongoing to take brain tumor targeting, and novel and targeted CNS delivery systems to potential clinical application.

show abstract

Changes in Blood-Brain Transfer Parameters Induced by Hyperosmolar Intracarotid Infusion and by Metastatic Tumor Growth

Cited by 32 publications

References 6 publications

Regional blood flow in ethylnitrosourea‐induced brain tumors

Regional blood flow in ethylnitrosourea‐induced brain tumors

Application of Quantitative Autoradiographic Measurements in Experimental Brain Tumor Models

Novel Treatment Strategies for Brain Tumors and Metastases

Contact Info

Product

Resources

About